Long-term follow-up of clinical trials of multiple sclerosis therapies
Long-term follow-up of clinical trials of multiple sclerosis therapies
复制标题
DOI：
10.1212/wnl.0b013e318205051d
复制
发表时间：
2011-01-04
期刊：
影响因子：
9.9
通讯作者：
Freedman, Mark S.
中科院分区：
文献类型：
--
作者：
Freedman, Mark S.
来自登记研究的结果可以提供关于不同形式的多发性硬化（MS）的患病率和临床病程的有价值的信息。这些研究还可以帮助确定在现实世界中的医疗实践模式和可能影响MS患者长期结局的重要风险因素。然而，到目前为止，这些观察性研究提供的信息比精心策划的随机对照试验少。短期临床试验结果表明，目前可用的DMT可有效减少疾病活动，表现为复发或MRI变化，并可减缓疾病进展。由于MS是一种慢性疾病，在30至40年的时间内演变，因此确定治疗的长期效果对患者和提供者都至关重要。本文讨论了MS患者中DMT的长期研究。迄今为止提供的探索性数据支持这一假设，即旨在减少疾病活动的早期最佳治疗可以通过延迟疾病进展来改善长期结局。神经病学2011; 76（增刊1）：S26-S34
Results from registry studies can provide valuable information about the prevalence and clinical course of different forms of multiple sclerosis (MS). Such studies can also help identify medical practice patterns in a real-world setting and important risk factors that may affect long-term outcomes in patients with MS. To date, however, these observational studies have provided less information than well-planned, randomized, controlled trials on the long-term treatment effects of disease-modifying therapies (DMTs). Short-term clinical trial results have indicated that currently available DMTs are effective in reducing disease activity, manifested by relapse or MRI change, and may slow disease progression. Because MS is a chronic disease that evolves over a period of 30 to 40 years, determining the long-term effects of treatment is of critical importance to both patients and providers. This article discusses long-term studies of DMTs in patients with MS. Exploratory data provided thus far support the hypothesis that early optimal treatment aimed at reducing disease activity can improve longer-term outcomes by delaying disease progression. NEUROLOGY 2011; 76(Suppl 1):S26-S34